Table 2 Main long-term outcomes
Author/year | Group | 5–8–10–12 year DFS | 5–8–10–12 year OS | 5–8–10–12 year LR | 5–8–10 year NR | Breast cancer deaths | Distant metastasis | Contralateral breast cancer | Second primary cancers |
|---|---|---|---|---|---|---|---|---|---|
Jayant 2020 [23] | APBI WBI | NR | 96.70%/–/88.62%/83.13% 97.69%/–/87.77%/84.72% | 3.96%/–/7.2%/7.2% 1.05%/–/2.8%/3.5% | NR | 3.61% 3.0% | 1.0% 1.4% | NR | NR |
Vicini 2019 [24] | APBI WBI | –/–/78.1%/– –/–/79.7%/– | –/–/90.6%/– –/–/91.3%/– | –/–/4.6%/– –/–/3.9%/– | NR | 2.3% 2.2% | 2.4% 3.1% | 3.0% 3.5% | 9% 10% |
Whelan 2019 [18] | APBI WBI | 96.4%/94.9%/–/ 96.8%/95.4%/–/ | 96.2%/93.6%/–/– 97%/94.3%/–/– | 2.3%/3%/–/– 1.7%/2.8%/–/– | –/0.4%/– –/0.2%/– | 1.7% 1.5% | 1.9% 1.7% | 2.7% 3.6% | 10.6% 9.0% |
APBI WBI | NR | NR | 0.5%/–/–/– 1.1%/–/–/– | 0.3%/–/– 0.1%/–/– | 1.5% 1.3% | 1.8% 1.9% | 1.9% 1.8% | 5.5% 7.0% | |
APBI WBI | 95.03%/–/–/– 94.45%/–/–/– | 97.27%/–/–/– 95.55%/–/–/– | 1·44%/–/–/– 0·92%/–/–/– | 0.47%/–/– 0.18%/–/– | 0.6% 0.7% | 0.8% 0.9% | 0.8% 0.9% | 5.5% 4.0% | |
APBI WBI | NR | 99.4%/–/–/– 96.6%/–/–/– | 1.5%/–/–/– 1.4%/–/–/– | 1.5%/–/– 1.9%/–/– | 0.4% 1.2% | 1.2% 1.5% | 1.2% 2.7% | NR | |
APBI WBI | NR | NR | 3.3%/–/–/– 1.3%/–/–/– | 0.5%/–/– 0.3%/–/– | 1.2% 0.9% | 0.5% 0.4% | NR | NR | |
Polgár 2013 [31] | APBI WBI | 88.8%/–/85.3%/– 90.5%/–/83.6%/– | –/–/79.7%/– –/–/82.1%/– | 4.0%/–/5.9%/– 3.3%/–/5.1%/– | 1.6%/–/2.5% 1.7%/–/1.7% | NR | 5.5% 8.5% | 7.0% 6.2% | 12.5% 10.8% |
Veronesi2013 [32] | APBI WBI | NR | 96.8%/–/–/– 96.9%/–/–/– | 4.4%/–/–/– 0.4%/–/–/– | 1.0%/–/– 0.3%/–/– | 3.5% 3.1% | 5.1% 5.4% | 1.2% 2.0% | 4.3% 5.4% |
Rodriguez 2013 [33] | APBI WBI | NR | NR | 0%/–/–/– 0%/–/–/– | 0%/–/– 0%/–/– | 0% 0% | 0% 0% | NR | 5.5% 7.0% |